Literature DB >> 18765124

Combination antimuscarinics and alpha-blockers for benign prostatic hyperplasia.

Scott A MacDiarmid1.   

Abstract

Millions of men suffer from lower urinary tract symptoms and overactive bladder. The adverse effects on quality of life and the costs associated with the condition have been well described. Although alpha-adrenergic antagonists have long been considered first-line therapy for male lower urinary tract symptoms, many patients have persistent storage symptoms and do not reach their treatment goal. Increasing data and clinical experience support the efficacy and safety of anticholinergics in men, either as monotherapy or in combination with alpha-blockers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18765124     DOI: 10.1007/s11934-008-0047-7

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  21 in total

Review 1.  The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Authors:  Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein
Journal:  Urology       Date:  2003-01       Impact factor: 2.649

2.  Self-assessed health, sadness and happiness in relation to the total burden of symptoms from the lower urinary tract.

Authors:  Gabriella Engström; Lars Henningsohn; Gunnar Steineck; Jerzy Leppert
Journal:  BJU Int       Date:  2005-04       Impact factor: 5.588

Review 3.  Natural history of benign prostatic hyperplasia.

Authors:  S J Jacobsen; C J Girman; M M Lieber
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

4.  Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings.

Authors:  M J Hyman; A Groutz; J G Blaivas
Journal:  J Urol       Date:  2001-08       Impact factor: 7.450

5.  High prevalence of benign prostatic hypertrophy in the community.

Authors:  W M Garraway; G N Collins; R J Lee
Journal:  Lancet       Date:  1991-08-24       Impact factor: 79.321

Review 6.  A neurologic basis for the overactive bladder.

Authors:  W C de Groat
Journal:  Urology       Date:  1997-12       Impact factor: 2.649

7.  The International Continence Society "Benign Prostatic Hyperplasia" Study: the botherosomeness of urinary symptoms.

Authors:  T J Peters; J L Donovan; H E Kay; P Abrams; J J de la Rosette; D Porru; J W Thüroff
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

8.  Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate.

Authors:  Ger E P M Van Venrooij; Harm H E Van Melick; Mardy D Eckhardt; Tom A Boon
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

9.  Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder.

Authors:  Ji Youl Lee; Hyun Woo Kim; Seung Ju Lee; Jun Sung Koh; Hong Jin Suh; Michael B Chancellor
Journal:  BJU Int       Date:  2004-10       Impact factor: 5.588

10.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

View more
  1 in total

1.  A survey of the FAERS database concerning the adverse event profiles of α1-adrenoreceptor blockers for lower urinary tract symptoms.

Authors:  Koji Yoshimura; Kaori Kadoyama; Toshiyuki Sakaeda; Yoshio Sugino; Osamu Ogawa; Yasushi Okuno
Journal:  Int J Med Sci       Date:  2013-05-15       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.